Clinical trial
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic…
NCT00081770 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00081770 |
|---|---|
| Title | Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) |
| Official title | Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1 |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Biological, Drug |
| Interventions | PegIntron (peginterferon alfa-2b, SCH 54031), REBETOL (ribavirin, SCH 18908), PEGASYS (peginterferon alfa-2a), COPEGUS (ribavirin) |
| Enrollment | 4,469 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Apr 22, 2004 |
| Last update posted | Apr 4, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: